eyonis LCS is a concurrent-reading aid for radiologists that detects, localizes, and characterizes 4-30 mm solid and part-solid pulmonary nodules on low-dose chest CT images for high-risk lung cancer screening patients; it provides nodule measurements and malignancy scores and does not replace physician judgment.
Clinical role
Concurrent-read CADe/CADx software that detects, localizes and characterizes pulmonary nodules on low-dose chest CT and generates a result report giving each nodule a malignancy score, displayed alongside the original CT images; it does not replace the interpreting physician's judgement.
Images and patients
CT/CTA · Chest/Lung
Key limitation
Does not replace physician judgment; intended for the stated 4-30 mm solid and part-solid nodule context and high-risk screening population.
Overview status: Field-derived fact summary This section is assembled from the sourced field records below; it is not a source-reviewed editorial overview.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
Imaging and anatomyCT/CTA · Chest/Lung
Workflow roleConcurrent-read CADe/CADx software that detects, localizes and characterizes pulmonary nodules on low-dose chest CT and generates a result report giving each nodule a malignancy score, displayed alongside the original CT images; it does not replace the interpreting physician's judgement.
Required inputLow-dose chest CT DICOM images from high-risk patients eligible for lung cancer screening programs (as per USPSTF criteria), excluding patients with pure ground glass cancer only and hilar/mediastinal cancer; exact specifications are described in a DICOM Conformance Statement.
Output and human actionNodule detection, localization, characterization, measurements, and malignancy scores for radiologist review.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
eyonis LCS is a concurrent-reading aid for radiologists that detects, localizes, and characterizes 4-30 mm solid and part-solid pulmonary nodules on low-dose chest CT images for high-risk lung cancer screening patients; it provides nodule measurements and malignancy scores and does not replace physician judgment.
Concurrent-read CADe/CADx software that detects, localizes and characterizes pulmonary nodules on low-dose chest CT and generates a result report giving each nodule a malignancy score, displayed alongside the original CT images; it does not replace the interpreting physician's judgement.
Exact FDA submission
Checked 2026-11-14
Packet wording: "eyonis® LCS is an AI/ML technology-based end-to-end CADe/CADx Software as a Medical Device (SaMD) designed to enable early detection, localization and characterization of pulmonary parenchymal nodules on low-dose Chest CT images" … "As an output, eyonis® LCS generates a result report that highlights probably benign, suspicious and very suspicious nodules and scores them individually by giving a malignancy score". Read from the exact FDA decision document on 2026-11-14.
Low-dose chest CT DICOM images from high-risk patients eligible for lung cancer screening programs (as per USPSTF criteria), excluding patients with pure ground glass cancer only and hilar/mediastinal cancer; exact specifications are described in a DICOM Conformance Statement.
Exact FDA submission
Checked 2026-11-14
Packet wording: "It is indicated for use with low-dose Chest CT DICOM images. The exact specifications are described in a DICOM Conformance Statement (DCS) document." … "The target population is high-risk patients eligible for participation in lung cancer screening programs (as per USPSTF criteria) with the exception of patients with pure ground glass cancer only and hilar/mediastinal cancer who are excluded from the intended population.". Read from the exact FDA decision document on 2026-11-14.
Two completed sponsor-registered retrospective studies describe Median LCS / eyonis LCS: RELIVE evaluated assisted versus unassisted reader accuracy in 480 high-risk lung-cancer screening cases, and REALITY evaluated standalone performance in 1,147 cases. The registry records identify the product family but not FDA submission K251474 or a software version.
Product family
Checked 2026-09-01
Registry records establish study design and enrollment, not peer-reviewed results or exact-version equivalence.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
Two completed sponsor-registered retrospective studies describe Median LCS / eyonis LCS: RELIVE evaluated assisted versus unassisted reader accuracy in 480 high-risk lung-cancer screening cases, and REALITY evaluated standalone performance in 1,147 cases. The registry records identify the product family but not FDA submission K251474 or a software version.
Public source
Product family
Checked 2026-09-01
Registry records establish study design and enrollment, not peer-reviewed results or exact-version equivalence.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
RELIVE: retrospective multi-reader, multi-case assisted-reading study
DesignCompleted retrospective observational cohort and controlled multi-reader, multi-case comparison
Population480 high-risk lung-cancer screening cases evaluated for pulmonary-nodule detection, localization, and characterization
Scopeproduct family
Tested versionMedian LCS / eyonis LCS; registry does not identify the FDA submission or software version
Samplen=480
IndependenceSponsor or vendor study
NCT06751576
Sponsor: Median Technologies. Primary endpoint compares reader patient-level AUROC with and without device assistance.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
Pricing & contractsPublic price, contract terms, and reimbursement
Medicare National Coverage Determination 210.14 (version effective 2022-02-10) covers annual lung cancer screening with low dose CT under Part B as a preventive service for eligible beneficiaries (age 50-77, asymptomatic, at least 20 pack-years, current smoker or quit within 15 years, with an order and a prior counseling and shared decision-making visit). It requires a board-certified or board-eligible reading radiologist and a facility that uses a standardized lung nodule identification, classification and reporting system. The NCD does not mention AI or nodule-detection software. This is national service-level context, not a determination that this exact product is covered or separately paid. No payment amount or software-specific code was reviewed.
National coverage of the LDCT lung screening service (NCD 210.14); software-specific coverage and payment not established
Medicare (Original Medicare, CMS) · United States · Effective 2022-02-10
The NCD covers the screening service and does not address AI software. It does not prove eligibility, coverage or separate payment for this product, version, patient, site or claim.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Low-dose chest CT DICOM images from high-risk patients eligible for lung cancer screening programs (as per USPSTF criteria), excluding patients with pure ground glass cancer only and hilar/mediastinal cancer; exact specifications are described in a DICOM Conformance Statement.
Scope: Exact FDA submission. Packet wording: "It is indicated for use with low-dose Chest CT DICOM images. The exact specifications are described in a DICOM Conformance Statement (DCS) document." … "The target population is high-risk patients eligible for participation in lung cancer screening programs (as per USPSTF criteria) with the exception of patients with pure ground glass cancer only and hilar/mediastinal cancer who are excluded from the intended population.". Read from the exact FDA decision document on 2026-11-14.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact-submission ACR model card explicitly references DICOM in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
Scope: Exact FDA submission. Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-10-27 ·
Returned objects
Source context, not route validation: Nodule detection, localization, characterization, measurements, and malignancy scores for radiologist review.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Nodule detection, localization, characterization, measurements, and malignancy scores for radiologist review.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact-submission ACR model card explicitly references DICOM in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
Exact FDA submission
Checked 2026-09-01
Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-04Last searched
20Fields reviewed
7Source classes checked
0Awaiting review PubMed leads
2Awaiting review trial leads
0Unreviewed FDA recall leads
Exact-submission ACR model-card fields were normalized under the current provenance rules; vendor and independent-study confirmation remain distinct. ClinicalTrials.gov candidate records were manually matched to the Median LCS / eyonis LCS product family; exact K251474 version equivalence was not established. Automated exact-name discovery found 0 PubMed and 2 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads remain unpublished until a human confirms the exact product and tested version.
Source classes: fda ai list, acr ai central product, clinical trials, payer policy, fda decision summary, pubmed, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-10-27 - Exact FDA submission
No public price or quote for the exact K251474 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Deployment: Not verified - checked 2026-10-27 - Exact FDA submission
The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not publicly available - checked 2026-10-26 - Exact FDA submission
Bounded search 2026-10-26: Median Technologies' eyonis.ai corporate-policies page covers patents, anti-corruption and fair competition only; the legal notice is a website disclaimer; no product security statement located.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-10-27 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-10-27 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Adjunctive pulmonary nodule detection and measurement, including temporal comparison, in chest CT screening of asymptomatic adults aged at least 55 years.
AI-Rad Companion (Pulmonary) is image processing software that provides quantitative and qualitative analysis from previously acquired Computed Tomography DICOM images to support radiologists and physicians from emergency medicine, specialty care, urgent care, and general practice in the evaluation and assessment of disease of the lungs. It provides the following functionality: Segmentation and measurements of complete lung and lung lobes Identification of areas with lower Hounsfield values in comparison to a predefined threshold for complete lung and lung lobes Providing an interface to external Medical Device syngo.CT Lung CAD Segmentation and measurements of solid lung nodules. Dedication of found lung nodules to corresponding lung lobe. Correlation of segmented lung nodules of current scan with known priors and quantitative assessment of changes of the correlated data. Identification of areas with elevated Hounsfield values, where areas with elevated versus high opacities are distinguished. The software has been validated for data from Siemens Healthineers (filtered back projection and iterative reconstruction),GE Healthcare (filtered back projection reconstruction), and Philips (filtered back projection reconstruction).Only DI COM images of adult patients are considered to be valid input.
Authorized purpose: Assist radiologists in detecting solid and subsolid pulmonary nodules during review of multivendor multi-detector CT examinations of the chest; the device is an adjunctive first- or second-reader tool.
Authorized purpose: Adjunctive detection of 3-20 mm pulmonary nodules in chest CT examinations for asymptomatic populations, including second-reader use.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.